MT2020-28: Ruxolitinib, Human Chorionic Gonadotropin (uhCG/EGF), and Dose De-escalated Corticosteroids for Treatment of Minnesota High-Risk Acute GVHD (aGVHD): A Phase I/II Study

Status: Recruiting

Eligibility Criteria

Sex: Male or Female
Age Group: Not specified
This study is NOT accepting healthy volunteers

Inclusion Criteria:

- Hematopoietic Cell Transplant (HCT) recipients over 12 years of age within the first 7 days of initial treatment of high-risk Acute-graft-versus-host Disease (aGVHD) - see link to clinicaltrials.gov for complete inclusion and exclusion criteria

Exclusion Criteria:

- progressive cancer - uncontrolled bacterial, fungal, parasitic, or viral infection - current thromboembolic disease requiring full-dose anticoagulation - active or recent (within prior 3 months) thrombus, irrespective of anticoagulation status - pregnancy - women or men of childbearing potential unwilling to take adequate precautions to avoid unintended pregnancy from the start of protocol treatment through 30 days after the last treatment

Conditions & Interventions

Interventions:
Drug: Corticosteroids, Drug: Ruxolitinib 10 MG Oral Tablet, Drug: hCG
Conditions:
Cancer
Keywords:
Clinics and Surgery Center (CSC), Acute-graft-versus-host Disease, aGVHD, HCT, Hematopoietic Cell Transplant

More Information

Description: The purpose of this study is to learn whether the use of Pregnyl with the drug ruxolitinib is able to reduce the need for high dose steroids to treat severe acute Graft versus Host Disease (GVHD).
Study Contact: Janine Delage - jdelage@umn.edu
Principal Investigator: Punita Grover
Phase: Phase 1/Phase 2
IRB Number: STUDY00014365